share_log

Xenon Pharmaceuticals Analyst Ratings

Xenon Pharmaceuticals Analyst Ratings

氙气制药分析师评级
Benzinga Analyst Ratings ·  2023/01/31 07:43
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 34.21% RBC Capital $49 → $51 Maintains Outperform
12/14/2022 57.89% Goldman Sachs → $60 Initiates Coverage On → Buy
12/12/2022 — Cowen & Co. Initiates Coverage On → Outperform
11/28/2022 31.58% Wells Fargo → $50 Initiates Coverage On → Overweight
11/11/2022 28.95% Guggenheim $53 → $49 Maintains Buy
10/19/2022 36.84% Raymond James → $52 Initiates Coverage On → Outperform
10/11/2022 28.95% RBC Capital $46 → $49 Maintains Outperform
08/29/2022 — B of A Securities Initiates Coverage On → Buy
08/11/2022 21.05% SVB Leerink $40 → $46 Maintains Outperform
08/10/2022 21.05% RBC Capital $41 → $46 Maintains Outperform
07/21/2022 44.74% JP Morgan → $55 Initiates Coverage On → Overweight
06/27/2022 7.89% Wedbush $47 → $41 Maintains Outperform
05/11/2022 7.89% RBC Capital $43 → $41 Maintains Outperform
11/11/2021 5.26% SVB Leerink $34 → $40 Maintains Outperform
10/28/2021 13.16% RBC Capital → $43 Initiates Coverage On → Outperform
10/04/2021 26.32% Needham $25 → $48 Maintains Buy
03/02/2021 -34.21% Needham $22 → $25 Maintains Buy
03/02/2021 -26.32% SVB Leerink $25 → $28 Maintains Outperform
10/02/2020 -42.11% SVB Leerink → $22 Initiates Coverage On → Outperform
07/21/2020 -42.11% Needham → $22 Initiates Coverage On → Buy
06/01/2020 -39.47% Jefferies $16 → $23 Assumes → Buy
03/25/2020 -39.47% Wedbush → $23 Initiates Coverage On → Outperform
01/08/2020 — William Blair Initiates Coverage On → Outperform
09/20/2019 -34.21% Guggenheim → $25 Initiates Coverage On → Buy
03/29/2019 — Stifel Assumes → Buy
08/08/2018 -60.53% Stifel $9 → $15 Maintains Buy
03/08/2018 -76.32% Stifel $7 → $9 Maintains Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/31/2023 34.21% 加拿大皇家銀行資本 $49 → $51 維護 跑贏大盤
12/14/2022 57.89% 高盛 → $60 開始承保 →購買
12/12/2022 — 考恩公司 開始承保 →跑贏大盤
11/28/2022 31.58% 富國銀行 → $50 開始承保 →超重
11/11/2022 28.95% 古根海姆 $53 → $49 維護 買
10/19/2022 36.84% 雷蒙德·詹姆斯 → $52 開始承保 →跑贏大盤
10/11/2022 28.95% 加拿大皇家銀行資本 $46 → $49 維護 跑贏大盤
08/29/2022 — B of A證券 開始承保 →購買
08/11/2022 21.05% SVB Leerink $40 → $46 維護 跑贏大盤
08/10/2022 21.05% 加拿大皇家銀行資本 $41 → $46 維護 跑贏大盤
07/21/2022 44.74% 摩根大通 → $55 開始承保 →超重
06/27/2022 7.89% 韋德布什 $47 → $41 維護 跑贏大盤
05/11/2022 7.89% 加拿大皇家銀行資本 $43 → $41 維護 跑贏大盤
11/11/2021 5.26% SVB Leerink $34 → $40 維護 跑贏大盤
10/28/2021 13.16% 加拿大皇家銀行資本 → $43 開始承保 →跑贏大盤
10/04/2021 26.32% 李約瑟 $25 → $48 維護 買
03/02/2021 -34.21% 李約瑟 $22 → $25 維護 買
03/02/2021 -26.32% SVB Leerink $25 → $28 維護 跑贏大盤
10/02/2020 -42.11% SVB Leerink → $22 開始承保 →跑贏大盤
07/21/2020 -42.11% 李約瑟 → $22 開始承保 →購買
06/01/2020 -39.47% 傑富瑞 $16 → $23 假設 →購買
03/25/2020 -39.47% 韋德布什 → $23 開始承保 →跑贏大盤
01/08/2020 — 威廉·布萊爾 開始承保 →跑贏大盤
09/20/2019 -34.21% 古根海姆 → $25 開始承保 →購買
03/29/2019 — Stifel 假設 →購買
08/08/2018 -60.53% Stifel $9 → $15 維護 買
03/08/2018 -76.32% Stifel $7 → $9 維護 買

What is the target price for Xenon Pharmaceuticals (XENE)?

氙氣製藥(Xene)的目標價是多少？

The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by RBC Capital on January 31, 2023. The analyst firm set a price target for $51.00 expecting XENE to rise to within 12 months (a possible 34.21% upside). 13 analyst firms have reported ratings in the last year.

加拿大皇家銀行資本於2023年1月31日報道了氙氣製藥(納斯達克代碼：XENE)的最新目標價。這家分析公司將目標價定為51.00美元，預計Xene將在12個月內上漲(可能上漲34.21%)。過去一年，有13家分析公司公佈了評級。

What is the most recent analyst rating for Xenon Pharmaceuticals (XENE)?

分析師對氙氣製藥(Xene)的最新評級是多少？

The latest analyst rating for Xenon Pharmaceuticals (NASDAQ: XENE) was provided by RBC Capital, and Xenon Pharmaceuticals maintained their outperform rating.

加拿大皇家銀行資本提供了對氙氣製藥(納斯達克代碼：XENE)的最新分析師評級，氙氣製藥維持其表現優於大盤的評級。

When is the next analyst rating going to be posted or updated for Xenon Pharmaceuticals (XENE)?

氙氣製藥(Xene)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Xenon製藥的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Xenon製藥的上一次評級是在2023年1月31日提交的，所以你應該預計下一次評級將在2024年1月31日左右的某個時候公佈。

Is the Analyst Rating Xenon Pharmaceuticals (XENE) correct?

分析師對Xenon製藥(Xene)的評級正確嗎？

While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a maintained with a price target of $49.00 to $51.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $38.00, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Xenon製藥(Xene)評級維持不變，目標價在49.00美元至51.00美元之間。Xenon PharmPharmticals(Xene)目前的交易價格為38.00美元，超出了分析師的預測區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論